分期伽玛刀联合贝伐珠单抗治疗散发性前庭神经鞘瘤的纵向肿瘤反应动态
该回顾性研究纳入72例散发性前庭神经鞘瘤患者,比较分期伽玛刀联合贝伐珠单抗(49例)与单次伽玛刀 alone(23例)的纵向肿瘤反应。联合治疗组显示更早且持续的肿瘤缩小,早期体积增大(>10%)发生率显著更低(14.3% vs 60.9%,HR 0.16),假性进展发生率数值上更低但无统计学差异(4.1% vs 17.4%,P=0.078)。
要点
- 分期GKRS联合贝伐珠单抗较单次GKRS alone显示更早且持续的肿瘤缩小。
- 联合治疗组早期体积增大(>10%)风险显著降低(HR 0.16,95%CI 0.06-0.40)。
- 假性进展发生率数值上更低(4.1% vs 17.4%),但差异无统计学意义(P=0.078)。
核心结论
- 分期伽玛刀联合贝伐珠单抗与散发性前庭神经鞘瘤更早、更持续的肿瘤缩小及更低的早期治疗后增大风险相关。
- 基线肿瘤体积较大和囊性成分与更明显的肿瘤缩小相关。
- 假性进展发生率数值上更低,但差异无统计学意义。
研究设计与样本
- 回顾性研究纳入72例散发性前庭神经鞘瘤患者,其中49例接受分期伽玛刀联合贝伐珠单抗,23例接受单次伽玛刀 alone。
- 纵向肿瘤体积变化采用多变量线性混合效应模型分析,早期体积增大采用Kaplan-Meier估计和Cox比例风险模型评估。
主要发现
- 与单次伽玛刀 alone相比,分期伽玛刀联合贝伐珠单抗显示显著不同的反应轨迹(治疗-时间交互作用,P < 0.001),表现为更早且持续的肿瘤缩小。
- 从3至36个月观察到更明显的肿瘤缩小(所有校正P < 0.05)。
- 早期体积增大(>10%)发生率分别为14.3%和60.9%(HR 0.16;95% CI 0.06-0.40;P < 0.001)。
- 假性进展发生率分别为4.1%和17.4%,无统计学显著性(P = 0.078)。
- 囊性肿瘤成分与更明显的肿瘤缩小独立相关。
临床怎么用
- 对于散发性前庭神经鞘瘤,分期伽玛刀联合贝伐珠单抗可能减少早期治疗后体积增大和假性进展的临床困扰。
- 基线肿瘤体积较大和囊性成分的患者可能从联合治疗中获得更明显的肿瘤缩小。
- 贝伐珠单抗相关不良事件轻微且可控,支持该联合方案的安全性。
局限性
- 回顾性研究设计。
- 两组样本量不平衡(49例 vs 23例)。
- 假性进展差异未达统计学显著性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Vestibular schwannomas (VSs) are benign tumors of the eighth cranial nerve. Although Gamma Knife radiosurgery (GKRS) achieves durable tumor control, delayed regression and pseudoprogression remain clinical challenges. Staged GKRS combined with bevacizumab may alter post-radiosurgical tumor response patterns. AIM: To compare longitudinal tumor response, pseudoprogression, and clinical outcomes between staged GKRS combined with bevacizumab and single-session GKRS alone in sporadic VSs. METHODS: We retrospectively reviewed 72 patients with sporadic VSs: 49 treated with staged GKRS plus bevacizumab and 23 with single-session GKRS alone. Longitudinal tumor volume changes were analyzed using multivariable linear mixed-effects models, while early volumetric enlargement was evaluated using Kaplan-Meier estimates and Cox proportional hazards models. RESULTS: Compared with GKRS alone, staged GKRS plus bevacizumab showed significantly different response trajectories (treatment-by-time interaction, P < 0.001), with earlier and sustained regression. Greater tumor reduction was observed from 3 to 36 months (all adjusted P < 0.05). Early volumetric enlargement (>10%) occurred in 14.3% versus 60.9% of patients (HR, 0.16; 95% CI, 0.06-0.40; P < 0.001). Pseudoprogression occurred in 4.1% versus 17.4% of patients, without statistical significance (P = 0.078). Cystic tumor composition was independently associated with greater regression. BEV-related adverse events were mild and manageable. CONCLUSION: Staged GKRS combined with bevacizumab was associated with earlier, more sustained tumor regression and a lower risk of early post-treatment enlargement in sporadic VSs. Larger baseline tumor volume and cystic composition were associated with greater regression. Pseudoprogression was numerically less frequent, although the difference was not statistically significant. TRIAL REGISTRATION: ChiCTR2600131856 (Chinese Clinical Trial Registry).
引用
- Peng, Wang, Cao, et al. Longitudinal tumor response dynamics after staged gamma knife radiosurgery combined with bevacizumab in sporadic vestibular schwannoma. Clin Transl Radiat Oncol. 2026. PMID: 42936495. doi:10.1016/j.ctro.2026.101318
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。